eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 68
Original paper

Expression of resistin in the liver of patients with non-alcoholic fatty liver disease

Piotr Gierej, Beata Gierej, Piotr Kalinowski, Tadeusz Wróblewski, Rafał Paluszkiewicz, Konrad Kobryń, Bogna Ziarkiewicz-Wróblewska

Pol J Pathol 2017; 68 (3): 225-233
Online publish date: 2017/11/30
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Adipokines are cytokines that presumably connect the pathologies of metabolic syndrome. One of the adipokines is resistin, the role of which in insulin resistance, obesity, and non-alcoholic fatty liver disease (NAFLD) needs to be determined. Liver biopsy specimens were obtained intraoperatively from 214 obese patients. Histological assessment was based on NAFLD activity score according to Kleiner. Statistical analysis involved semi-quantitive immunohistochemistry assessment of resistin staining and: NAFLD status in obese patients compared with a non-obese control group, selected clinical data (age, sex, body mass index – BMI), selected biochemical data, comorbidities (hypertension, type 2 diabetes mellitus, dyslipidaemia), and metformin treatment in patients with type 2 diabetes mellitus. Resistin expression was observed in the histiocytes of inflammatory infiltrate, Kupffer cells, and histiocytes surrounding the hepatocytes with steatosis. There was a positive correlation between the total expression of resistin and: (1) NAFLD advancement (NAFLD Activity Score- NAS), (2) AST, ALT, BMI, glucose, insulin, Homeostasis Model Assessment (HOMA), LDH, GGT, triglycerides (TG), and glycated haemoglobin (HbA1c). Resistin expression was more intense in patients with type 2 diabetes mellitus and dyslipidaemia and less intense in the control group. Resistin probably plays a role in the pathogenesis of hepatic insulin resistance and aggravates pathologic changes in the liver of patients with NAFLD.

adipokines, insulin resistance, steatohepatitis, obesity

Orlik B, Handzlik G, Olszanecka-Glinianowicz M. The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease. Postepy Hig Med Dosw 2010; 64: 212-219.
Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-1198.
Shen C, Zhao CY, Wang W, et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014; 23: 14-39.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
Huang F, Del-Rio-Navarro BE, Pérez-Ontiveros JA, et al. Effect of six-month lifestyle intervention on adiponectin, resistin and soluble tumor necrosis factor- receptors in obese adolescents. Endocr J 2014; 61: 921-931.
Szalowska E, Elferink MG, Hoek A, et al. Resistin is more abundant in liver than adipose tissue and is not up-regulated by lipopolysaccharide. J Clin Endocrinol Metab 2009; 94: 3051-3057.
Pagano C, Soardo G, Pilon C, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086.
Jiang LL, Li L, Hong XF, et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 2009; 21: 662-666.
Bajaj M, Suraamornkul S, Hardies LJ, et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004; 28: 63-69.
Stejskal D, Adamovska S, Bartek J, et al. Resistin: concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap 2003; 147: 63-69.
Wong VW, Hui AY, Tsang SW, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1154-1161.
Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421.
Krawczyk K, Szczesniak P, Kumor A, et al. Adipohormones as prognostic markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol 2009; 60: 71-75.
Perseghin G, Lattuada G, De Cobelli F, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab 2006, 91: 5122-5125.
Hui J, Farrell GC, Kench JG, et al. High sensitivity CRP protein values do not reliably predict the severity of histologic change in NAFLD. Hepatology 2004; 39: 1458-1459.
Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian Men. J Gastroenterol Hepatol 2004; 19: 694-698.
Senateş E, Colak Y, Yeş il A, et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores. Minerva Med 2012; 103: 369-376.
Lee YS, Cho YK, Pae JC, et al. The relationship between serum adiponectin level and serum alanine aminotransferase elevation in Korean male with nonalcoholic fatty liver disease. Korean J Hepatol 2006; 12: 221-229.
Boyraz M, Cekmez F, Karaoglu A, et al. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease. Biomark Med 2013; 7: 737-745.
Quatanani M, Szwergold NR, Greaves DR, et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009; 119: 531-539.
Pravenec M, Kazdová L, Landa V, et al. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem 2003; 278: 45209-45215.
Rajala MW, Obici S, Scherer PE, et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230.
Rangwala SM, Rich AS, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941.
Satoh H, Nguyen MT, Miles PD, et al. Adenovirus-mediated chronic “hyperresistinemia” leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114: 224-231.
Steppan CM, Wang J, Whiteman EL, et al. Activation of SOCS-3 by resistin. Mol Cell Biol 2005; 25: 1569-1575.
Chen BH, Song Y, Ding EL, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009; 32: 329-334.
Kapłon-Cieślicka A, Postuła M, Rosiak M, et al. Association of adipokines and inflammatory markers with lipid control in type 2 diabetes. Pol Arch Intern Med 2015; 125: 414-423.
Moschen A, Molnar C, Wolf AM, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009; 51: 765-777.
Edwards C, Hindle AK, Latham PS, et al. Resistin expression correlates with steatohepatitis in morbidly obese patients. Surg Endosc 2013; 27: 1310-1314.
Edwards C, Hindle AK, Fu S, et al. Downregulation of leptin and resistin expression in blood following bariatric surgery. Surg Endosc 2011; 25: 1962-1968.
Santoro S, Milleo FQ, Malzoni CE, et al. Enterohormonal changes after digestive adaptation: five-year results of a surgical proposal to treat obesity and associated diseases. Obes Surg 2008; 18: 17-26.
Fujinami A, Obayashi H, Ohta K, et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004; 339: 57-63.
Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
Cruz-Dominguez MP, Cortés DH, Zarate A, et al. Relationship of ghrelin, acid uric and proinflammatory adipocytokines in different degrees of obesity or diabetes. Int J Clin Exp Med 2014; 7: 1435-1441.
Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, et al. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004; 53: 1279-1284.
Panidis D, Koliakos G, Kourtis A, et al. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 361-366.
Silha JV, Murphy LJ. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2004; 89: 1977-1978.
Malo E, Ukkola O, Jokela M, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions In the Finnish Health 2000 survey. Metab Syndr Relat Disord 2011; 9: 203-210.
Baranova A, Gowder SJ, Schlauch K, et al. Gene expression of leptin, resistin and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16: 1118-1125.
Youn BS, Yu KY, Park HJ, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150-156.
Cabrera de León A, Almeida González D, González Hernández A, et al. Relationship between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb 2014; 21: 454-462.
Liu Y, Wang Q, Pan YB, et al. Effects of over-expressing resistin on glucose and lipid metabolism in mice. J Zhejiang Univ Sci 2008; 9: 44-50.
Al-Daghri N, Chetty R, McTernan PG, et al. Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005; 5: 4-10.
De Luis DA, Sagrado MG, Conde R, et al. Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naïve diabetes obese patients. Diabetes Res Clin Pract 2010; 89: 110-114.
Uslu S, Kebapçi N, Kara M, et al. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med 2012; 4: 113-120.
Piestrzeniewicz K, Łuczak K, Komorowski J, et al. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 2008; 57: 488-493.
Zheng H, Xu H, Xie N, et al. Association of serum resistin with peripheral arterial disease. Pol Arch Intern Med 2013; 123: 680-685.
Adaikalakoteswari A, Jayashiri R, Sukumar N, et al. Vitamin B12 deficiency is associated with adverse lipid profile in Europeans and Indians with type 2 diabetes. Cardiovasc Diabetol 2014; 13: 129.
Niafar M, Hai F, Porhomayon J, et al. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med 2015; 10: 93-102.
Ahmad A, Afroz N, Gupta UD, et al. Vitamin B12 supplement alleviates N’-nitrosodimethylamine-induced hepatic fibrosis in rats. Pharm Biol 2014; 52: 516-523.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe